免疫标志物动态变化与意义未明单克隆丙种球蛋白血症进展为多发性骨髓瘤的关联
该前瞻性队列研究纳入685例MGUS患者,纵向分析显示53%的进展者在进展前已呈高危MGUS,其中70%在5年内由低/中危转化而来,提示动态风险评估与每年血液检测的必要性。
要点
- IgA型、M蛋白≥15 g/L、血清游离轻链比值异常和严重免疫麻痹与进展风险独立相关。
- 纵向监测中53%的进展者在进展前已呈高危MGUS,其中70%在5年内由低/中危转化。
- 研究支持对MGUS或轻链MGUS患者每年进行血液检测和风险评估。
核心结论
- MGUS进展风险模式随时间演变,支持每年血液检测和风险评估。
研究设计与样本
- 前瞻性横断面队列研究,纳入前列腺、肺、结直肠和卵巢癌筛查试验筛查臂中55至74岁成人77 469例,其中进展性MGUS 187例、稳定性MGUS 498例,获取系列储存的预测前血清样本3266份。
主要发现
- 在进展前有系列样本的参与者中,43例中23例(53%)在进展前已呈高危MGUS,其中16例(70%)在5年内由低危或中危MGUS转化。
关键数值与推荐
- 与进展性MGUS相关的风险因素:IgA同型、M蛋白峰≥15 g/L、血清游离轻链比值<0.1或>10、严重免疫麻痹(≥2种未受累免疫球蛋白受抑)。
- 与进展性轻链MGUS相关的风险因素:血清游离轻链比值<0.1或>10、严重免疫麻痹(≥2种未受累免疫球蛋白受抑)。
临床怎么用
- 对MGUS或轻链MGUS患者应每年进行血液检测和风险评估。
- 动态监测免疫标志物变化有助于识别由低/中危向高危转化的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup. OBJECTIVE: To longitudinally investigate the alterations of serum immune markers with stable vs progressive MGUS. DESIGN, SETTING, AND PARTICIPANTS: This prospective cross-sectional cohort study included 77 469 adult participants aged 55 to 74 years in the screening arm of the National Cancer Institute Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who had a diagnosis of progressing MGUS (n = 187) or stable MGUS (n = 498), including light-chain subtype, from November 1993, through December 2011. For each participant, all available serially stored prediagnostic serum samples (N = 3266) were obtained. Data analysis was performed from April 2018, to December 2018. MAIN OUTCOMES AND MEASURES: Serum protein and monoclonal immunoglobulin levels, serum free light chains, and serum light chains within each immunoglobulin class were measured. RESULTS: Of 685 individuals included in the study, 461 (67.3%) were men; the mean (SD) age was 69.1 (5.6) years. In cross-sectional modeling, risk factors associated with progressive MGUS were IgA isotype (adjusted odds ratio [OR], 1.80; 95% CI, 1.03-3.13; P = .04), 15 g/L or more monoclonal spike (adjusted OR, 23.5; 95% CI, 8.9-61.9; P < .001), skewed (<0.1 or >10) serum free light chains ratio (adjusted OR, 46.4; 95% CI, 18.4-117.0; P < .001), and severe immunoparesis (≥2 suppressed uninvolved immunoglobulins) (adjusted OR, 19.1; 95% Cl, 7.5-48.3; P < .001). Risk factors associated with progressive light-chain MGUS were skewed serum free light chains ratio (adjusted OR, 44.0; 95% CI, 14.2-136.3; P < .001) and severe immunoparesis (adjusted OR, 48.6; 95% CI, 9.5-248.2; P < .001). In longitudinal analysis of participants with serial samples prior to progression, 23 of 43 participants (53%) had high-risk MGUS before progression; 16 of these 23 (70%) experienced conversion from low-risk or intermediate-risk MGUS within 5 years. Similar results were found for light-chain MGUS. CONCLUSIONS AND RELEVANCE: The findings of evolving risk patterns support annual blood testing and risk assessment for patients with MGUS or light-chain MGUS.
引用
- Landgren O, Hofmann JN, McShane CM, et al. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncol. 2019. PMID: 31318385. doi:10.1001/jamaoncol.2019.1568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。